Picture of AstraZeneca logo

AZN — AstraZeneca Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+9.95%
3m+14.13%
6m+34.5%
1yr+26.95%
Volume Change (%)
10d/3m-27.79%
Price vs... (%)
52w High-2.71%
50d MA+3.82%
200d MA+15.86%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)18.03
PEG Ratio (f)0.47
EPS Growth (f)62.46%
Dividend Yield (f)2.33%
Valuation (ttm)IndustryMarket
Price to Book Value5.55
Price to Tang. Bookn/a
Price to Free Cashflow39
Price to Sales4.86
EV to EBITDA32.03

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital0.05%
Return on Equity-4.19%
Operating Margin0.09%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m22,46522,09024,38426,61737,41743,184.4846,243.6210.22%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-45.74-37.64+73.89+27.14+17.96+198.15+17.2n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for AZN

What lies in store for the AstraZeneca share price? background image

What lies in store for the AstraZeneca share price?

Economic uncertainty remains a major concern in many industry sectors. For investors in well known companies like AstraZeneca (LON:AZN), the question is: where will prices go from here? AstraZeneca is part of an elite club of UK shares...

Are analysts upbeat on the outlook for AstraZeneca? background image

Are analysts upbeat on the outlook for AstraZeneca?

While the world wrestles with the impact of Covid, inflation and geopolitical strife, investors are naturally wondering what lies in store for some of the country's largest quoted companies, such as AstraZeneca (LON:AZN).  AstraZeneca...

Do analysts think that Astrazeneca is a buy, hold or sell? background image

Do analysts think that Astrazeneca is a buy, hold or sell?

Buy, hold and sell recommendations from company analysts can be a useful signal about the sentiment around a stock. Examining the 'consensus' rating among brokers can give you a sense of whether the share is worth buying or not. Take A...

Is there momentum behind the Astrazeneca share price? background image

Is there momentum behind the Astrazeneca share price?

It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Astrazeneca (LON:AZN) will go fr...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of AstraZeneca EPS forecast chart

Profile Summary

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
June 17th, 1992
Public Since
September 21st, 2007
No. of Shareholders
74,520
No. of Employees
83,100
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
1,549,470,612

AZN Share Price Performance

Similar to AZN

Picture of Abcam logo

Abcam

gb flag iconLondon Stock Exchange

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of Benchmark Holdings logo

Benchmark Holdings

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email